Avantor, Inc. (AVTR) Current Ratio
- Current ratio · latest quarter: Value 1.76×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.76× | Current assets / current liabilities. $2.40B ÷ $1.37B ≈ 1.76× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 2.40B USD | Assets, Current |
| Current obligations | 1.37B USD | Liabilities, Current |
| Cash and equivalents | 279.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 1.10B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 810.30M USD | Inventory, Net |
| Payables | 735.50M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 37.00M USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $2.40B | $1.37B | $279.30M | (m) | $1.10B | $810.30M | $735.50M | $37.00M | 1.76× |
| 2025-12-31 | $2.45B | $1.38B | $365.40M | (m) | $1.07B | $818.20M | $741.70M | $30.80M | 1.78× |
| 2025-09-30 | $2.26B | $1.52B | $251.90M | (m) | $1.08B | $795.50M | $691.60M | $219.80M | 1.49× |
| 2025-06-30 | $2.51B | $2.58B | $449.40M | (m) | $1.15B | $779.80M | $708.80M | $1.25B | 0.98× |
| 2025-03-31 | $2.28B | $2.03B | $315.70M | (m) | $1.10B | $750.10M | $680.10M | $827.50M | 1.12× |
| 2024-12-31 | $2.15B | $2.01B | $261.90M | (m) | $1.03B | $731.50M | $662.80M | $821.10M | 1.07× |
| 2024-09-30 | $2.50B | $1.63B | $285.30M | (m) | $1.09B | $779.60M | $673.50M | $229.70M | 1.54× |
| 2024-06-30 | $2.33B | $1.46B | $272.60M | (m) | $1.13B | $795.60M | $657.40M | $258.40M | 1.59× |
| 2024-03-31 | $2.32B | $1.44B | $234.90M | (m) | $1.13B | $810.60M | $573.40M | $299.10M | 1.61× |
| 2023-12-31 | $2.38B | $1.48B | $262.90M | (m) | $1.15B | $828.10M | $625.90M | $259.90M | 1.61× |
| 2023-09-30 | $2.38B | $1.49B | $236.90M | (m) | $1.15B | $850.30M | $655.80M | $335.60M | 1.60× |
| 2023-06-30 | $2.50B | $1.55B | $236.40M | (m) | $1.22B | $890.40M | $686.60M | $314.00M | 1.61× |
| 2023-03-31 | $2.63B | $1.67B | $294.60M | (m) | $1.28B | $904.00M | $765.70M | $325.20M | 1.57× |
| 2022-12-31 | $2.66B | $1.66B | $372.90M | (m) | $1.22B | $913.50M | $758.20M | $364.20M | 1.60× |
| 2022-09-30 | $2.56B | $1.55B | $265.60M | (m) | $1.23B | $905.00M | $768.90M | $280.60M | 1.65× |
| 2022-06-30 | $2.57B | $1.57B | $237.50M | (m) | $1.27B | $922.50M | $798.60M | $246.40M | 1.64× |
| 2022-03-31 | $2.61B | $1.45B | $283.60M | (m) | $1.35B | $896.00M | $818.20M | $44.70M | 1.80× |
| 2021-12-31 | $2.48B | $1.45B | $301.70M | (m) | $1.22B | $872.00M | $755.10M | $45.20M | 1.71× |
| 2021-09-30 | $3.56B | $1.32B | $1.43B | (m) | $1.18B | $844.00M | $698.80M | $37.00M | 2.70× |
| 2021-06-30 | $2.42B | $1.38B | $223.00M | (m) | $1.27B | $840.90M | $755.30M | $39.50M | 1.76× |
| 2021-03-31 | $2.23B | $1.24B | $172.50M | (m) | $1.20B | $777.70M | $706.40M | $26.50M | 1.80× |
| 2020-12-31 | $2.23B | $1.24B | $286.60M | (m) | $1.11B | $739.60M | $678.90M | $26.40M | 1.80× |
| 2020-09-30 | $2.30B | $1.14B | $370.50M | (m) | $1.04B | $729.80M | $625.30M | $14.40M | 2.02× |
| 2020-06-30 | $2.29B | $1.05B | $415.30M | (m) | $983.70M | $737.80M | $581.00M | $14.30M | 2.18× |
| 2020-03-31 | $2.20B | $1.13B | $346.30M | (m) | $1.04B | $686.10M | $610.90M | $14.30M | 1.95× |
| 2019-12-31 | $2.02B | $1.07B | $186.70M | (m) | $988.80M | $711.20M | $560.20M | $93.50M | 1.88× |
| 2019-09-30 | $2.02B | $1.08B | $173.90M | (m) | $983.30M | $714.50M | $556.30M | $41.40M | 1.87× |
| 2019-06-30 | $2.03B | $1.19B | $164.60M | (m) | $1.00B | $727.70M | $578.40M | $195.70M | 1.71× |
| 2018-12-31 | $1.90B | $1.10B | $184.70M | (m) | $931.20M | $671.10M | $557.40M | $142.40M | 1.73× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |